Abstract 424P
Background
Radiotherapy is a primary or an adjuvant treatment for most brain tumor patients for better tumors control and prolong survival [1]. However, cranial irradiation may cause damages to hippocampus (plural: hippocampi), which may induce dementia after they recovered from the disease [2]. To minimise radiation dose to hippocampus becomes a new trend in radiation therapy [3], [4]. This study is to investigate whether traditional coplanar VMAT (CO-VMAT) or proposed non-coplanar VMAT (NC-VMAT) is dosimetrically superior for brain tumor radiotherapy treatment in view of hippocampus sparing.
Methods
Both CO-VMAT plan and NC-VMAT plan were generated for 16 brain tumor patients (Glioblastoma: 11, Meningioma: 5) using Varian Eclipse planning system version 15.6. The prescription was to give 54 Gy to PTV in 30 fractions. Dose constraints applied for plan optimization were benchmarked against Radiation Therapy Oncology Group (RTOG). In the CO-VMAT plans, there were 1 full arc (179°-181°) and 2 half arcs. The couch angle for all arcs were 0°. For cases with PTV located at the left side of the brain, the gantry angle for the 2 half arcs were set from 0°to 179° and 179° to 0°. While for cases with PTV on the right side of the brain, the gantry angle of the 2 half arcs were set from 0° to 181°and 181°to 0°. In the NC-VMAT plans, all setting were the same as CO-VMAT plans, except that the couch angle for the 2 half arcs was at 315° for PTV located at the left side of the brain, and 45° for PTV located on the right side of the brain.
Results
Homogeneity index, conformation number, dose to other organs at risk and ipsilateral hippocampus were similar in CO-VMAT and NC-VMAT plans. The maximum dose (D-MaxCH) received by contralateral hippocampus in NC-VMAT is 4Gy lower (p=0.049) than that of the CO-VMAT. The dose received by 40 % of the contralateral hippocampus (D40%CH) in NC-VMAT is 1.46Gy (p=0.003) lower than that of the CO-VMAT. The mean D-MaxCH and mean D40%CH were reduced by 23% and 23.5% respectively in NC-VMAT plans when compared with CO-VMAT.
Conclusions
The NC-VMAT is able to minimize radiation dose to contralateral hippocampus while maintaining good plan quality. The NC-VMAT approach may help to consolidate the development of a new standard of care for brain tumor patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tung Wah College.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session